Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.35 |
| ▸ | TK2 | O00142 | 3/20 | 0.34 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112758 | 0.86 | TYMP (0.40) | TK1TYMP | |
| SCHEMBL5134596 | 0.84 | TK1 (0.40) | TK1TK2TYMP | |
| SCHEMBL8592454 | 0.83 | RNASE1 (0.44) | TK1TK2RNASE1TYMP | |
| SCHEMBL6852152 | 0.83 | TYMP (0.48) | TK1TK2TYMP | |
| SCHEMBL9294173 | 0.83 | TYMP (0.37) | TK1TK2TYMP | |
| SCHEMBL5223357 | 0.81 | — | — | |
| SCHEMBL6536270 | 0.80 | TK1 (0.39) | TK1TK2TYMP | |
| SCHEMBL9564565 | 0.77 | TK1 (0.52) | TK1 | |
| SCHEMBL7535867 | 0.77 | TK1 (0.52) | TK1 | |
| SCHEMBL60737 | 0.77 | TK1 (0.52) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10478449-B2 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180200282-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180104272-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180104271-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9943539-B1 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9943538-B1 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180028555-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9827263-B2 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150366894-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | ISIS PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| WO-2004044132-A2 | MODIFIED OLIGONUCLEOTIDES FOR USE IN RNA INTERFERENCE | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004044133-A2 | MODIFIED OLIGONUCLEOTIDES FOR USE IN RNA INTERFERENCE | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043977-A2 | 2’-FLUORO SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040102618-A1 | Human RNase H1 and oligonucleotide compositions thereof | ISIS PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6737520-B2 | FOR USE AS SUBSTRATE FOR RIBONUCLEASE AND CONTROLLING BINDING AFFINITY/NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | disclosed |
| US-6617442-B1 | Divided into two portions, one of which supports cleavage of target RNA; use in enhancing antisense therapies | ISIS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| US-20030096979-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | ISIS PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6369209-B1 | AFFINITY AND NUCLEASE RESISTANCE WHILE CONCURRENTLY SERVING AS SUBSTRATES FOR RNASE H WHEN BOUND TO A TARGET RNA STRAND | ISIS PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6271358-B1 | FOR INHIBITING SPECIFIC GENE EXPRESSION; HAVING ENHANCED HYBRID BINDING AFFINITY AND/OR INCREASED NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105311-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | TK1 661/4885TK2 1005/4885RNASE1 5/4885 |
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | TK1 2727/4885TK2 2210/4885RNASE1 107/4885 |
| US-20180200282-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | TK1 2727/4885TK2 2210/4885RNASE1 107/4885 |
| US-10478449-B2 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | NSUN2, SNRPE, RBM3 | TK1 2648/4885TK2 2209/4885RNASE1 108/4885 |
| US-20150366894-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | TK1 2727/4885TK2 2210/4885RNASE1 107/4885 |
| US-20030096979-A1 | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | RNGTT, RNASEH1, ADAR | TK1 661/4885TK2 1005/4885RNASE1 5/4885 |
| US-20180028555-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | TK1 2727/4885TK2 2210/4885RNASE1 107/4885 |
| US-20040102618-A1 | Human RNase H1 and oligonucleotide compositions thereof | RNASEH1, RNASE1, RNASEL | TK1 433/4885TK2 260/4885RNASE1 2/4885 |
| US-20180104272-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | TK1 2727/4885TK2 2210/4885RNASE1 107/4885 |
| US-20180104271-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | TK1 2727/4885TK2 2210/4885RNASE1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.